A STUDY OF THE ANTIOXIDANT EFFECTS OF IRANIAN CAPTOPRIL ON PATIENTS WITH HYPERTENSION AND HEART FAILURE
Publish place: ARYA Atherosclerosis، Vol: 1، Issue: 4
Publish Year: 1385
نوع سند: مقاله ژورنالی
زبان: English
View: 104
This Paper With 5 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_RYA-1-4_005
تاریخ نمایه سازی: 3 شهریور 1401
Abstract:
Abstract INTRODUCTION: Myocardial ischemia, cerebral ischemia and myocardial infarction are the most important complications of hypertension and atherosclerotic disease in developing countries. Angiotensin converting enzyme (ACE) inhibitors are among the drugs used to treat hypertension and heart failure. Captopril is an ACE-inhibitor which also has antioxidant properties. This study was conducted to assess the antioxidant effects of Iranian Captopril on malondialdehyde (MDA), conjugated dienes (CD) and serum antioxidant capacity before and after treatment. methods: This interventional prospective single-blind study was conducted on ۳۴ mildly hypertensive individuals and ۳۴ patients with stage I and II heart failure. MDA, CD and serum antioxidant capacity were measured in all samples. The patients were then given ۵۰ mg Captopril tablets ۲-۳ times daily. The measurements were repeated ۱.۵ months later. results: Comparison of mean MDA, CD and serum antioxidant capacity in hypertensive patients and patients with heart failure before and after drug administration revealed no significant difference in any of the parameters studied. Discussion: Existing evidence is suggestive of the strong antioxidative properties of Captopril in vitro, although these effects have not been borne out by some studies. In the present study, comparison of MDA, CD and serum antioxidants before and after the period of treatment with Iranian Captopril did not reveal any statistically significant difference.Keywords • Antioxidant • ACE inhibitor • High blood pressure • Heart failure • Clinical trial
Authors
Sedighe Asgari
PhD. Associate Professor, Pharmacognosist, Basic Sciences Department, Isfahan Cardiovascular Research Center.
Masoumeh Sadeghi
MD. Assistant Professor, Cardiologist, CVD in Women Department. Isfahan Cardiovascular Research Center.
Gholam-Ali Naderi
PhD. Associate Professor, Biochemist, Basic Research Department, Isfahan Cardiovascular Research Center.
Afshan Akhavan
MD. Research Assistant, Isfahan Cardiovascular Research Center.